



Electrochemotherapy as Treatment for Head and Neck Tumors

Guest Editors:

Dr. Francesco Longo

1. Hospital "Casa Sollievo della Sofferenza" IRCCS – San Giovanni Rotondo, Foggia, Italy
2. Istituto Nazionale Tumori IRCCS - Fondazione G Pascale, Napoli, Naples, Italy

Dr. Barbara Pichi

National Cancer Institute Regina Elena" IRCCS, Roma, Rome, Italy

Dr. Francesco Perri

Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Via Mariano Semmola, 80131 Napoli, Italy

Deadline for manuscript submissions:

closed (30 November 2022)

Message from the Guest Editors

Dear Colleagues,

Electrochemotherapy is a treatment combining a low dose of antineoplastic drug (bleomycin) and an electrical pulse (electroporation) applied directly to the cancer cells using an electrode. Electroporation consists of the application of short, intense, pulsed electric fields to tumor cells, with a transient increase of membrane permeability, facilitating cellular uptake of cytotoxic agents and increasing their toxicity.

Electrochemotherapy is indicated for the local treatment of solid tumors; it is a well-established antitumor strategy for cutaneous neoplasms and has interesting applications for the treatment of head and neck tumors. In fact, it is effective with any tumor regardless of the histotype and has several mechanisms of action with vascular and immunologic effects, ensuring good control of bleeding lesions and interesting prospects for the general care of cancer patients.

The interest in electrochemotherapy for the treatment of tumors in the head and neck area has increased because it results in minimal or no impacts to function and can lead to healing of treated tumor lesions without damage to the healthy tissues.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)